Drug Profile
Vismodegib - Roche
Alternative Names: Erivedge; GDC-0449; R 3616; RG 3616Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Curis
- Developer Centre Hospitalier Univeristaire De Lille; Clinica Universidad de Navarra; Erasmus Hospital; Genentech; National Cancer Institute (USA); Roche; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Class Antineoplastics; Benzamides; Small molecules; Sulfones
- Mechanism of Action Hedgehog cell-signalling pathway inhibitors; SMO protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Basal cell cancer
- Phase II Basal cell nevus syndrome; Chondrosarcoma; Gastric cancer; Medulloblastoma; Pancreatic cancer; Small cell lung cancer; Triple negative breast cancer
- Discontinued Acute myeloid leukaemia; B-cell lymphoma; Breast cancer; Chronic lymphocytic leukaemia; Colorectal cancer; Glioblastoma; Graft-versus-host disease; Idiopathic pulmonary fibrosis; Myelodysplastic syndromes; Myelofibrosis; Ovarian cancer; Prostate cancer; Sarcoma